X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2242) 2242
humans (1338) 1338
animals (1230) 1230
steroid 17-alpha-hydroxylase - genetics (1086) 1086
female (1082) 1082
steroid 17-alpha-hydroxylase - metabolism (1076) 1076
male (1038) 1038
endocrinology & metabolism (788) 788
rats (380) 380
adult (356) 356
abridged index medicus (335) 335
biochemistry & molecular biology (323) 323
middle aged (282) 282
steroid 17-alpha-hydroxylase - antagonists & inhibitors (266) 266
steroidogenesis (256) 256
cytochrome p-450 (251) 251
expression (239) 239
mice (235) 235
rna, messenger - metabolism (224) 224
cells, cultured (219) 219
cholesterol side-chain cleavage enzyme - genetics (208) 208
cytochrome p-450 enzyme system - metabolism (206) 206
testosterone (197) 197
aromatase - metabolism (196) 196
cyp17 (186) 186
gene expression (185) 185
aged (182) 182
pregnancy (182) 182
reproductive biology (179) 179
genotype (176) 176
molecular sequence data (173) 173
testis - enzymology (173) 173
kinetics (171) 171
3-hydroxysteroid dehydrogenases - metabolism (169) 169
progesterone - metabolism (168) 168
aromatase - genetics (166) 166
base sequence (163) 163
enzymes (163) 163
steroids - biosynthesis (163) 163
steroid 17-alpha-hydroxylase (162) 162
testis - metabolism (162) 162
oncology (161) 161
androgens - biosynthesis (157) 157
cholesterol side-chain cleavage enzyme - metabolism (156) 156
adolescent (155) 155
aldehyde-lyases - metabolism (153) 153
immunohistochemistry (150) 150
cattle (149) 149
microsomes - enzymology (147) 147
mutation (142) 142
testosterone - blood (139) 139
estrogen (138) 138
side-chain cleavage (132) 132
androgens (131) 131
prostate cancer (131) 131
polymorphism, genetic (129) 129
case-control studies (128) 128
physiological aspects (128) 128
progesterone (128) 128
cytochrome p-450 enzyme system - genetics (126) 126
gene (126) 126
testosterone - biosynthesis (126) 126
steroid hydroxylases - metabolism (124) 124
3-hydroxysteroid dehydrogenases - genetics (121) 121
rna, messenger - genetics (121) 121
cell biology (116) 116
analysis (115) 115
adrenal glands - metabolism (113) 113
obstetrics & gynecology (113) 113
metabolism (112) 112
risk factors (112) 112
steroid 17-alpha-hydroxylase - biosynthesis (112) 112
gene-expression (110) 110
article (109) 109
cell line (109) 109
biosynthesis (108) 108
polymerase chain reaction (108) 108
testis - drug effects (107) 107
genes (106) 106
cells (105) 105
steroids (105) 105
steroid 17-alpha-hydroxylase - chemistry (104) 104
women (104) 104
genetic aspects (103) 103
leydig cells - metabolism (103) 103
genetic predisposition to disease (101) 101
phosphoproteins - genetics (101) 101
amino acid sequence (100) 100
aromatase (100) 100
rats, sprague-dawley (100) 100
rna, messenger - analysis (100) 100
steroids - metabolism (100) 100
research (99) 99
androgens - metabolism (98) 98
ovary - metabolism (98) 98
pregnenolone - metabolism (98) 98
reverse transcriptase polymerase chain reaction (98) 98
17-hydroxysteroid dehydrogenases - metabolism (96) 96
adrenal hyperplasia, congenital - genetics (96) 96
testosterone - metabolism (96) 96
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2261) 2261
Japanese (25) 25
Chinese (15) 15
Russian (10) 10
French (9) 9
German (2) 2
Polish (2) 2
Korean (1) 1
Portuguese (1) 1
Spanish (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature, ISSN 0028-0836, 07/2015, Volume 523, Issue 7560, pp. 347 - 351
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5... 
ANDROGEN RECEPTOR | 3-BETA-HYDROXYSTEROID DEHYDROGENASE | CYP17A1 INHIBITION | MECHANISM | TESTOSTERONE | RATIONALE | MULTIDISCIPLINARY SCIENCES | INCREASED SURVIVAL | CHEMOTHERAPY | EXPOSURE | ENZALUTAMIDE | Chromatin - metabolism | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Androgens - biosynthesis | Male | Androstenes - pharmacology | Androgen Receptor Antagonists - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Biotransformation | Cell Division | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | 3-Hydroxysteroid Dehydrogenases - metabolism | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms - pathology | Androstenes - therapeutic use | 5-alpha Reductase Inhibitors - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Phenylthiohydantoin - analogs & derivatives | Androgen Receptor Antagonists - metabolism | Xenograft Model Antitumor Assays | Androstenes - chemistry | Animals | Biosynthetic Pathways - drug effects | Survival Analysis | 5-alpha Reductase Inhibitors - pharmacology | Androstenes - metabolism | Prostatic Neoplasms - enzymology | Mice | Steroid 17-alpha-Hydroxylase - metabolism | 5-alpha Reductase Inhibitors - metabolism | Androgens - metabolism | Enzymes | Testosterone | Androgens | Metabolites | Ligands | Gene expression | Prostate cancer | Tumors | Index Medicus
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 1, pp. 53 - 60
Abstract Background Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC). Objective To evaluate... 
Urology | Castration-resistant prostate cancer | Primary resistance to enzalutamide | Androgen signaling inhibition | Bone metastasis | Bone tumor microenvironment | Adaptive feedback mechanism | Androgen receptor | Predictors of outcome | Enzalutamide | Tissue-based research | TESTOSTERONE | CHEMOTHERAPY | RECEPTOR SPLICE VARIANTS | THERAPY | DEPRIVATION | CLINICAL-TRIALS | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | PROGRESSION | ABIRATERONE | Prospective Studies | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Receptors, Androgen - metabolism | Retroviridae Proteins, Oncogenic - metabolism | Bone Neoplasms - secondary | Cytoplasm - metabolism | Drug Resistance, Neoplasm | Ki-67 Antigen - metabolism | Male | Antineoplastic Agents - therapeutic use | Receptors, Glucocorticoid - metabolism | Prostatic Neoplasms, Castration-Resistant - pathology | Bone Neoplasms - metabolism | Cell Nucleus - metabolism | Protein Isoforms - metabolism | Bone Marrow - metabolism | Aged, 80 and over | Adult | Bone Neoplasms - drug therapy | Testosterone - blood | Gene Dosage | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Bone Marrow Neoplasms - secondary | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Receptors, Androgen - genetics | Signal Transduction - drug effects | Bone Marrow Neoplasms - metabolism | Aged | Bone Marrow Neoplasms - drug therapy | Steroid 17-alpha-Hydroxylase - metabolism | Prostate cancer | Metastasis | Index Medicus | Bone marrow biopsy | Androgen | Antiandrogens
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 01/2018, Volume 293, Issue 2, pp. 541 - 556
Cytochrome P450 (P450) 17A1 catalyzes the oxidations of progesterone and pregnenolone and is the major source of androgens. The enzyme catalyzes both... 
Hydroxysteroids - metabolism | Animals | Humans | Cytochrome P-450 Enzyme System - metabolism | Protein Conformation | Zebrafish | Steroid 17-alpha-Hydroxylase - metabolism | Index Medicus | biomimetic models | Enzymology
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer | Index Medicus
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 02/2012, Volume 97, Issue 2, pp. 507 - 516
Context: Abiraterone acetate is a small-molecule cytochrome P450 17A1 (CYP17A1) inhibitor that is active in castration-resistant prostate cancer. Objective:... 
TRIAL | HUMAN CYTOCHROME P450(17-ALPHA) | ANDROGEN RECEPTOR | PATHWAY | STEROIDAL INHIBITORS | GUIDELINES | ENDOCRINOLOGY & METABOLISM | KETOCONAZOLE | ACETATE | DIHYDROTESTOSTERONE | REMAINS | Androstenols - adverse effects | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Glucocorticoids - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Enzyme Inhibitors - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Chemotherapy, Adjuvant | Glucocorticoids - adverse effects | Prostatic Neoplasms - drug therapy | Biomarkers - metabolism | Carcinoma - drug therapy | Enzyme Inhibitors - adverse effects | Biomarkers, Pharmacological - analysis | Antineoplastic Agents, Hormonal - pharmacology | Prostatic Neoplasms - surgery | Androstenols - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Carcinoma - surgery | Biomarkers - analysis | Enzyme Inhibitors - pharmacology | Androstenes | Treatment Outcome | Disease Progression | Orchiectomy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Androstenols - administration & dosage | Steroid 17-alpha-Hydroxylase - metabolism | Carcinoma - metabolism | Biomarkers, Pharmacological - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 03/2014, Volume 383, Issue 1-2, pp. 111 - 117
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2011, Volume 60, Issue 5, pp. 897 - 904
Abstract Background Abiraterone acetate (AA) is an androgen biosynthesis inhibitor shown to prolong life in patients with castration-resistant prostate cancer... 
Urology | Biomarker | TMPRSS2-ERG fusion | Circulating tumor cells | Abiraterone | Prostate-specific antigen | Prostate cancer | NUMBER | TESTOSTERONE | DOCETAXEL | GENE FUSIONS | WORKING GROUP | THERAPY | RECOMMENDATIONS | ANDROGEN-RECEPTOR | CLINICAL-TRIALS | UROLOGY & NEPHROLOGY | EXPRESSION | Predictive Value of Tests | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Neoplastic Cells, Circulating - pathology | Humans | Neoplastic Cells, Circulating - metabolism | Male | Abiraterone Acetate | Patient Selection | New York City | Prostatic Neoplasms - genetics | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Reproducibility of Results | Prostatic Neoplasms - surgery | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Survival Rate | Treatment Outcome | Genetic Markers | Reverse Transcriptase Polymerase Chain Reaction | Enzyme Inhibitors - therapeutic use | Prostatic Neoplasms - mortality | Orchiectomy | Oncogene Proteins, Fusion - genetics | Prostatic Neoplasms - enzymology | Prostatectomy | Androstadienes - therapeutic use | Biomarkers, Tumor - genetics | Steroid 17-alpha-Hydroxylase - metabolism | Antigens | Care and treatment | Chemotherapy | Metastasis | Acetates | Cancer | Cells | Tumor cells | Proteinase | Serine | biomarkers | Clinical trials | Reverse transcription | Survival | Blood | Polymerase chain reaction | Androgens | Acetic acid | Growth factors | Prostate | Oncogenes | Tumors | prostate-specific antigen | Index Medicus
Journal Article